{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:06:27Z","timestamp":1783595187622,"version":"3.55.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Rituximab has been approved in Japan for the treatment of intractable nephrotic syndrome, but in cases of childhood-onset disease only; its efficacy and safety in adult-onset disease has yet to be established. This study was undertaken to evaluate the efficacy of rituximab and adverse effects in patients with adult-onset minimal change nephrotic syndrome (MCNS).<\/jats:p>\n            <jats:p>The study involved 32 childhood-onset cases (mean age at onset: 8.6 years) and 19 adult-onset cases (mean age at onset: 30.6 years) of frequently relapsing steroid-dependent MCNS, all of whom received intravenous rituximab drip infusion (375\u200amg\/m<jats:sup>2<\/jats:sup> body surface area per dose) at 4 time points at 6-month intervals. Relapse frequency, oral dose of immunosuppressants, and adverse effects were compared between the 2 groups.<\/jats:p>\n            <jats:p>Remission was maintained in all cases in the childhood-onset and adult-onset groups; a significant reduction in relapse frequency was noted during the first 24 months of rituximab therapy (0.3\u200a\u00b1\u200a0.7 times and 0.3\u200a\u00b1\u200a0.6 times in the childhood-onset and adult-onset groups, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). Oral corticosteroid therapy could be discontinued in 81.3% of cases of the childhood-onset group (26\/32 cases) and in 70.6% of cases of the adult-onset group (12\/17 cases); the oral corticosteroid dose was reduced significantly to 0.9\u200a\u00b1\u200a2.5\u200amg\/day in the childhood-onset group and to 0.8\u200a\u00b1\u200a1.6\u200amg\/day in the adult-onset group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). Cyclosporin treatment was also discontinued in 87.5% of cases in the childhood-onset group (21\/24 cases) and in 80.0% of cases of the adult-onset group (15\/21 cases); the oral cyclosporin dose was reduced significantly to 8.6\u200a\u00b1\u200a27.4\u200amg\/day and 9.2\u200a\u00b1\u200a22.0\u200amg\/day, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). Regarding adverse reactions, infusion reactions developed at a frequency of 21.1% and 19.7% in both groups, respectively, with no significant inter-group difference (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.72).<\/jats:p>\n            <jats:p>Rituximab showed significant efficacy in adult-onset MCNS, with a comparable incidence of adverse reactions to that in childhood-onset cases, suggesting that this drug can also be used safely in adult-onset MCNS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000012704","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T23:14:10Z","timestamp":1539818050000},"page":"e12704","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease"],"prefix":"10.1097","volume":"97","author":[{"given":"Yuko","family":"Iwabuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoei","family":"Miyabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/ndt\/gfm592","article-title":"Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy","volume":"23","author":"Yang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CNP72069","article-title":"Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome","volume":"72","author":"Sawara","year":"2009","journal-title":"Clin Nephrol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2169\/internalmedicine.48.2435","article-title":"Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome","volume":"48","author":"Kurosu","year":"2009","journal-title":"Intern Med"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"c98","DOI":"10.1159\/000319656","article-title":"Effect of single-dose rituximab on primary glomerular diseases","volume":"117","author":"Sugiura","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","article-title":"Effect of single-dose rituximab on steroid-dependent minimal change nephrotic syndrome in adults","volume":"28","author":"Takei","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1097\/MD.0000000000000300","article-title":"Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment","volume":"93","author":"Iwabuchi","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10157-015-1139-6","article-title":"Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome","volume":"20","author":"Miyabe","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"46036","DOI":"10.1038\/srep46036","article-title":"Cost-effectiveness of administering rituximab for steroid-dependent nephrotic syndrome and frequently relapsing nephrotic syndrome: a preliminary study in Japan","volume":"7","author":"Takura","year":"2017","journal-title":"Sci Rep"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R13-20230914","first-page":"16","article-title":"The efficacy of rituximab in adult frequently relapsing minimal change disease","volume":"10","author":"King","year":"2017","journal-title":"Clin Kidney J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201810190-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:49:43Z","timestamp":1694713783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201810190-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":13,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000012704","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}